You are here:Home-Research Areas-Neurological Disease-Schizophrenia

Request The Product List ofSchizophrenia Schizophrenia

Cat. No. Product Name CAS No. Information
PC-63187

RP-5063

1239729-06-6

RP-5063 (Brilaroxazine) is a multimodal dopamine and serotonin modulator with partial agonist activity at DA D2, D3, D4, 5-HT1A, and 5-HT2ARs, and antagonist activity at 5-HT2B, 5-HT6 and 5-HT7Rs; produces dose-dependent reductions in pulmonary blood vessel wall thickness and proportion of muscular vessels, blocks MCT-induced increases in the plasma cytokines TNFα, IL-1β, and IL-6 in vivo; prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats; improves declarative memory and psychosis in mouse models of schizophrenia.

Schizophrenia

Phase 2 Clinical

PC-61511

AVN-211

1173103-84-8

AVN-211 (CD-008-0173) is a novel and highly selective 5-HT6 receptor small molecule antagonist with Ki of 2.34 nM; shows a similar or better anxiolytic efficacy than fenobam, rufinamide, lorazepam, and buspirone in an elevated plus-maze model; significantly delayes or partially halts the progressive decline in memory function associated with AD.

Schizophrenia

Phase 3 Clinical

PC-61105

MIN-101

359625-79-9

MIN-101 (Roluperidone, CYR-101, MT-210) is a higly potent 5-HT2A and sigma 2 receptor antagonist, with no direct dopamine affinities, for treatment of negative symptoms in schizophrenia.

Schizophrenia

Phase 3 Clinical

PC-60564

PF 05180999

1394033-54-5

PF-05180999 (PF 5180999) is a potent, selective, brain-penetrating and orally bioavailable phosphodiesterase 2A (PDE2A) inhibitor with IC50 of 1 nM; displays >1,000-fold selectivity over PDE10; shows potential for treatment of schizophrenia.

Schizophrenia

Phase 1 Discontinued

PC-60563

TAK-915

1476727-50-0

TAK-915 (TAK915) is a highly potent, selective, brain-penetrating and orally active phosphodiesterase 2A (PDE2A) inhibitor with IC50 of 0.61 nM; dispalys 4100-fold selectivity over PDE1A, and >20,000-fold over other PDE isoforms; robustly increased cGMP levels in the rat brain, attenuates MK-801-induced episodic memory deficits in rats.

Schizophrenia

Phase 1 Clinical

PC-60496

AMG-579

1227067-61-9

AMG-579 is a potent, selective, CNS penetrant, orally bioavailable PDE10A inhibitor with IC50 of 0.1 nM; displays high selectivity with IC50 > 30 uM against all other PDE isoforms; demonstrates excellent target occupancy efficacy in PCP-LMA behavioral model.

Schizophrenia

Phase 1 Clinical

PC-70076

Lumateperone

313368-91-1

Lumateperone (ITI-007) is a potent 5-HT2A antagonist (Ki=0.54 nM), postsynaptic D2 antagonist(Ki=32 nM), and SERT blocker (Ki= 61 nM); also shows affinity for D1; orally bioavailable and exhibits good antipsychotic efficacy in vivo.

Schizophrenia

Phase 3 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com